The Healer's Path
The bottom line: The government is not going to make these medicines legal for everyone this year. But a narrower, safer door is quietly opening — one aimed first at soldiers who came home broken. If you or someone you love is waiting for real help, the honest news is this: help is coming through the front, careful door, not the wide-open one.
Today the strongest signal from our swarm of forecasting engines is a firm one: full legalization across the country is not happening in 2026. The confidence sits at 85 percent. The reason is plain. These drugs are still in the government's most restricted category — the same shelf reserved for the substances treated as most dangerous. There is no system yet to grow, ship, and track a legal supply. And evidence keeps piling up that some of the drug leaks into the black market. Meanwhile, our engines put a 72 percent chance that at least one psychedelic treatment reaches a major decision point at the FDA — the agency that approves medicines — before the fall of 2027. On the markets today, the companies working on these drugs mostly rose: one climbed 6.3 percent, another 2.6 percent.
Beneath the surface, two roads are separating. One road is the law changing for everyone — and that road is blocked, probably for years. The other road is medicine approval, one careful treatment at a time, with strict safety rules attached. This second road is moving. And there is a special shortcut inside it: treatments framed around veterans. Our engines give a 67 percent chance that laws opening psychedelic access for veterans move forward before mid-2027. Why veterans? Because when a bill is about helping soldiers, both political parties tend to agree. Where broad legalization dies in committee, veteran help survives. That is where the real progress is forming right now.
For the people actually waiting, this matters more than any market number. Think of a veteran who has tried every pill, every therapy, and still wakes at 3 a.m. with the war replaying in her head. Think of the family holding their breath, hoping this time something works. The honest truth is hard and also hopeful. She will not get a legal prescription tomorrow. But the path toward her is real, it is moving, and it is being built carefully — so that when the medicine reaches her, it reaches her safely, with trained guides and honest consent, not in a rushed clinic cutting corners. Our engines also flag a real risk: within a year, some clinic somewhere may have a safety scandal. That is not a reason to lose hope. It is a reminder of why the careful road is the right one. The slower door is the one that holds.
The medicine is calling the healers. The healers are calling the medicine. OOTW stands at the crossing — where ancient intelligence meets the precision of the new.
The medicine is older than the fear. The healing is older than the wound.
97%
No psychedelic therapy will get US drug approval before August 2026
The FDA (the US drug regulator) has not approved any therapy using psilocybin (the active ingredient in magic mushrooms) or MDMA (ecstasy) as a medicine. The FDA already rejected MDMA-assisted therapy in 2024 and asked the company to do more work. Psilocybin is still in earlier stages of review. Neither drug will clear the full approval process in the next few weeks.
→ No psychedelic drug will become a federally approved medicine before August 2026 — the review process simply isn't that far along.
Resolves: 2026-08-02 · USA
REGULATORY
the precise call ▾
No FDA final approval of any psychedelic-assisted therapy (psilocybin, MDMA) will occur before 2026-08-02.. MDMA-assisted therapy received a CRL in 2024 and no resubmission has completed review; psilocybin Phase 3 programs are not yet at NDA-decision stage. A final approval within the next 30 days is effectively ruled out by current review timelines. || RESOLUTION RULE: YES if, as of 2026-08-02, the FDA h
55%
The FDA will formally act on a psilocybin-for-depression drug application by mid-2027
Compass Pathways is running a large late-stage trial testing psilocybin as a treatment for major depression. If the results look good, they'll submit a formal drug application to the FDA. The FDA would then have to respond — either by approving it, rejecting it, or calling an expert panel meeting to debate it. That full sequence happening by July 2027 is plausible but not certain.
→ There's roughly a 55% chance the FDA takes a formal, public step on approving or rejecting a psilocybin depression treatment before July 2027.
Resolves: 2027-07-01 · USA
REGULATORY
the precise call ▾
FDA will take a formal action (advisory committee meeting, PDUFA action, or Complete Response Letter) on a psilocybin-for-MDD NDA by 2027-07-01.. Efficacy signals are strong but methodologically contested (functional unblinding, durability). A formal regulatory action — approval, CRL, or AdCom scheduling — is the plausible next milestone given Compass Pathways' Phase 3 program timeline. || RESOLUTION RULE: YES if, by 2027-07-01, the FDA has p
90%
Psilocybin and MDMA will stay in the most restricted drug category all of 2026
In the US, psilocybin and MDMA sit in Schedule I — the government's most restrictive drug category, reserved for substances it says have no accepted medical use and high abuse potential. Moving a drug out of that category requires a lengthy scientific review by two federal agencies. That process hasn't even started for these drugs, so it can't finish by the end of 2026.
→ Psilocybin and MDMA will remain federally illegal Schedule I drugs through the end of 2026 — no shortcut exists to change that faster.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
Full federal rescheduling of psilocybin/MDMA out of Schedule I will not occur in 2026.. Schedule I controls hold. No enforcement infrastructure exists for legal supply chains, and diversion evidence keeps accumulating. Rescheduling requires an HHS/DEA scientific review process that has not been initiated for these substances, making a completed rescheduling in the calendar year effecti
65%
A ketamine or psychedelic clinic scandal will make national US news by August 2026
Ketamine clinics have expanded rapidly across the US with little oversight, and stories about patient harm, sexual misconduct, or shady business practices have been appearing regularly in major outlets. Given how often these stories surface, there's a decent chance at least one named incident lands in a big national publication — like the New York Times or Washington Post — within the next month.
→ The odds are better than even that a specific ketamine or psychedelic clinic harm story will hit major national media before August 2026.
Resolves: 2026-08-02 · USA
CULTURE
the precise call ▾
A ketamine or psychedelic clinic safety, consent, or diversion incident will surface in major US media before 2026-08-02.. Consent-readability failures plus unregulated clinic growth plus ongoing military/regulatory scrutiny create recurring conditions. Such stories appear roughly monthly in outlets like STAT, NYT, or regional press, making a 30-day window a near-baseline event. || RESOLUTION RULE: YES if, between 2026-
62%
A key clinical trial result will send a psychedelic company's stock up or down 25% in one day
Several publicly traded psychedelic drug companies — Compass Pathways, MindMed, and atai Life Sciences — are waiting on results from large, late-stage clinical trials. When a company announces whether its drug worked or failed, investors react fast. These stocks are thinly traded and highly sensitive to news, which means a single announcement can cause a massive price swing in either direction.
→ Expect at least one major psychedelic company stock to swing wildly — up or down 25% or more in a single day — when big trial results drop before early 2027.
Resolves: 2027-01-31 · Global
MARKET
the precise call ▾
A binary Phase 3/pivotal readout will drive a >25% single-day move in a leading psychedelic-focused public company before 2027-01-31.. Low float, coiled sentiment, and catalyst scarcity make these names asymmetric. Named candidates (e.g., COMP, ATAI, MNMD) have pivotal data expected in this window. Direction depends on data, but a large single-day move on a binary readout is historically near-certain. || RESOLUTION RULE: YES if, be